Genomic Solutions Brings Losses, Tumbling Stock for Harvard Bioscience | GenomeWeb

Harvard Bioscience last week reported that its Genomic Solutions business was a “major disappointment” in the first quarter of 2004, and that the company may consolidate the business to cut costs — announcements that sent its stock plunging by 50 percent during the week.

Genomic Solutions took in $2 million less than expected, according to the company — pushing Harvard Bioscience out of the profitability zone. The company experienced a net loss of $51,000 for the quarter, compared with a net income of $776,000 in the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.